Aprea expands cancer trial sites and plans Q4 2026 data update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aprea expands cancer trial sites and plans Q4 2026 data update

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

July 30, 2026 8:00 AM EDT

Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051Enrollment in ACESOT-1051 is accelerating as the Company advances dose escalation and amasses the clinical data needed to inform dose selection and subsequent developmentAprea plans to advance APR-1051 in uterine serous carcinoma (USC) and Cyclin Eoverexpressing platinum-resistant ovarian cancer (PROC) while also evaluating combination regimens with standard of care... More